EUCTR2013-002654-75-NL进行中（未招募）1 期
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 348
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed consent form (ICF) for this extension study signed by the subject or legally acceptable representative and an ICF signed by the support person/caregiver before initiation of any study-specific extension procedures
- •2. Successful completion (Day 182) of study EVP-6124-024 or EVP-6124-025
- •3. No clinically significant change in the judgment of the investigator in the subject’s medical status during study EVP-6124-024 or EVP-6124-025
- •4. In the judgment of the investigator, extension treatment is in the best interest of the subject
- •5. Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study. Female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or Protocol EVP-6124-026; 12 September 2013 Page 9 of 66 Forum Pharmaceuticals Inc. CONFIDENTIAL EVP-6124 bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])
- •6. Reliable and capable support person/caregiver, who if not living in the same household, interacts with the subject approximately 4 times per week and will be available to attend clinic visits in person when possible
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 158
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1422
排除标准
- •1. Significant risk of suicidal or violent behavior in the judgment of the investigator
- •2. Adverse events (AEs) from the previous study (EVP-6124-024 or EVP-6124-025) that have not resolved, are moderate or severe, judged to be possibly related or related to study drug, and considered by the investigator to be a contraindication to extension study participation
- •3. Any condition that would make the subject in the judgment of the investigator unsuitable for the study
- •4. Female subjects who are pregnant, nursing, or planning to become pregnant during the extension study
研究者
相似试验
进行中（未招募）
1 期
Study of the safety and effectiveness of investigational study drug EVP-6124 in subjects with Alzheimer's DiseaseAlzheimer’s DiseaseMedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disordersMedDRA version: 17.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disordersEUCTR2013-002654-75-GBForum Pharmaceuticals Inc.348
进行中（未招募）
1 期
Study of the safety and effectiveness of investigational studydrug EVP-6124 in subjects with Alzheimer's DiseaseEUCTR2013-002654-75-DEForum Pharmaceuticals Inc.1,300
进行中（未招募）
不适用
Study of the safety and effectiveness of investigational studydrug EVP-6124 in subjects with Alzheimer's DiseaseAlzheimer’s DiseaseMedDRA version: 17.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 17.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-002654-75-ITForum Pharmaceuticals Inc.1,580
进行中（未招募）
不适用
Study of the safety and effectiveness of investigational studydrug EVP-6124 in subjects with Alzheimer's DiseaseEUCTR2013-002654-75-BEForum Pharmaceuticals Inc.1,580
进行中（未招募）
不适用
Study of the safety and effectiveness of investigational studydrug EVP-6124 in subjects with Alzheimer's DiseaseEUCTR2013-002654-75-CZForum Pharmaceuticals Inc.1,580